How The Right Dose Can Turn THC Into An Ally Against Alzheimer's

The study showed that low doses of tetrahydrocannabinol, especially when combined with an anti-inflammatory drug, can reduce brain changes associated with Alzheimer's disease and protect memory in animal models. Because these medications are already approved, this combination has great potential for clinical trials in humans.

Alzheimer's disease is the most common cause of dementia in older people and represents one of the greatest current public health challenges. Millions of people worldwide live with this disease, and this number is expected to grow rapidly in the coming decades. Despite scientific advances, there are still no truly effective treatments capable of preventing, halting, or reversing the progression of Alzheimer's. Therefore, finding new therapeutic strategies is urgent.

A promising approach is the repurposing of medications that are already approved and used for other conditions. This path can accelerate the development of new therapies, as these medications have already had their safety tested in humans. Within this context, cannabis, and especially its main active compound, tetrahydrocannabinol, has begun to be investigated as a possible ally in the fight against Alzheimer's.

Previous laboratory and animal studies have shown that tetrahydrocannabinol (THC) can reduce the accumulation of proteins associated with Alzheimer's disease, especially beta-amyloid, a substance that deposits in the brain and is linked to neuronal death.

These results suggest that THC could have a protective effect on the brain. However, its therapeutic use is limited by psychiatric and cognitive side effects, such as mental confusion and memory impairment, especially at higher doses.

Another important challenge is that tetrahydrocannabinol (THC) exhibits different effects depending on the dose used. High doses tend to impair cognition, while lower doses appear to improve learning and memory in older animals.

This difference makes it difficult to find a safe and effective dose, which has delayed the advancement of research focused on using this compound to treat or prevent Alzheimer's disease.

Furthermore, inflammation in the brain plays a central role in the development of Alzheimer's disease. Inflammation can both accelerate the progression of the disease and act as an initial trigger. Anti-inflammatory drugs have been tested in the past, but when used in isolation, they have not demonstrated clear benefits for the prevention of Alzheimer's in humans.

Interestingly, THC can reduce inflammation in some contexts, but it can also activate specific inflammatory pathways in the brain, which contributes to its negative effects on memory.

Given this, researchers hypothesized that combining a low dose of tetrahydrocannabinol (THC) with a specific anti-inflammatory drug could maintain the benefits of THC while simultaneously blocking its harmful effects. To test this idea, they used an anti-inflammatory that inhibits an enzyme directly involved in brain inflammation associated with cognitive impairment.

In the study, animal models of Alzheimer's disease received low doses of THC, alone or in combination with this anti-inflammatory. Researchers evaluated several aspects: the accumulation of toxic proteins in the brain, the health of connections between neurons, performance on memory and learning tests, and the activity of genes related to inflammation and brain function.

The results showed that treatment with low-dose THC significantly reduced the deposits of proteins associated with Alzheimer's, improved communication between neurons, and prevented the onset of cognitive decline.

These effects were even stronger when THC was combined with the anti-inflammatory. The combination also helped to normalize the activity of genes that were dysregulated in Alzheimer's, including genes linked to inflammation and synaptic function.

In conclusion, the study suggests that combining a low dose of tetrahydrocannabinol with a specific anti-inflammatory drug could transform a compound known for its side effects into a promising therapeutic strategy against Alzheimer's disease.

Since both medications are already approved and used clinically, this approach has high potential for rapid testing in human studies, especially for preventing or delaying the onset of the disease.

READ MORE:

A Combination of Low-Dose Δ9-THC and Celecoxib as a Therapeutic Strategy for Alzheimer’s Disease

Jian Zhang, Dexiao Zhu, Mei Hu, Mingzhe Pan, and Chu Chen

Aging and Disease. 18 December 2025.

DOI: 10.14336/AD.2025.1206

Abstract:

Alzheimer’s disease (AD) is the leading cause of dementia in the elderly, and no effective therapies are currently available to prevent, treat, or halt its progression. Δ9-Tetrahydrocannabinol (Δ9-THC), the primary psychoactive compound in marijuana, has been considered a potential therapeutic agent, but clear evidence for its ability to prevent cognitive decline is lacking. Previous studies have demonstrated that Δ9-THC-induced cognitive impairments are associated with the induction of cyclooxygenase-2 (COX-2). In this study, we aimed to evaluate whether Δ9-THC alone or in combination with Celecoxib, a selective COX-2 inhibitor, could reduce neuropathology and improve cognitive function in AD model animals. We observed that Δ9-THC (3.0 mg/kg), either alone or with Celecoxib (1.0 mg/kg), significantly reduced Aβ and tau pathologies, enhanced synaptic marker expression, and prevented the onset of cognitive decline. Notably, the combination treatment produced greater improvements in spatial learning and effectively mitigated Δ9-THC-induced neuroinflammatory responses. Furthermore, Δ9-THC reversed or attenuated the dysregulated expression of synaptic and immune/inflammation-related genes and restored the downregulated expression of genes linked to AD observed in both AD patients and AD animal models, with greater efficacy when combined with Celecoxib in AD model mice. These findings suggest that the combination of low-dose Δ9-THC and Celecoxib holds promise as an early intervention strategy for preventing AD onset or treating mild cognitive impairment (MCI). Importantly, both Δ9-THC (in the form of Dronabinol and Nabilone) and Celecoxib are FDA-approved medications already in clinical use, supporting the strong translational potential of this combination therapy and its feasibility for rapid advancement to clinical trials to assess its efficacy in preventing or delaying AD onset in humans.